Quarterly Earnings

As Jabil preps its Q2 FY26 report, investors watch to see if the AI boom can sustain its momentum amid global economic and supply chain pressures.

Canadian General Investments posts a 35.3% share price gain, yet its NAV lags the benchmark. A deep dive into its portfolio, leverage, and market position.

As markets grow top-heavy, Intech's math-driven ETFs gain traction by turning diversification and volatility into a systematic source of returns.

As its stock stumbles, web-game leader CTW heads to the Roth Conference to prove its unique anime IP and HTML5 model can deliver long-term growth.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Despite a full-year GAAP loss, AFC declares a dividend and shifts its strategy post-BDC conversion. Can it resolve legacy loans and find new growth?

After a rough earnings report sent its stock tumbling, WEBTOON Entertainment heads to key investor conferences to pitch its long-term IP and creator vision.

With record 2025 revenue and a dominant hold on the gene therapy market, Cryoport's strategic investments pave a path toward profitability.

After a strong Q4, Amprius launches a strategic roadshow to pitch its high-energy silicon anode batteries to investors and key aerospace and defense players.

The neurohealth firm surpassed revenue estimates and hit positive cash flow, but a dynamic competitive landscape and CEO transition loom ahead of its earnings call.

Amid a booming gene therapy market, Oxford Biomedica Solutions launches key investor events to showcase its strategy and secure its leadership position.

LendingTree posts a record $319.7M Q4 driven by its insurance arm, yet an adjusted loss spooks investors. Can its AI-powered strategy win them back?

Riot Platforms reports a record $647M revenue for 2025, but a staggering net loss and a strategic pivot to data centers raises critical questions.

James River Group flips a $94M loss to a $30.1M profit, driven by strategic underwriting, cost cuts, and a pivotal move from Bermuda to Delaware.

Colombia's energy giant is set to reveal its 2025 performance, testing its diversification strategy against falling oil prices and high investor expectations.

After a major turnaround, Genetix Biotherapeutics announces its first profitable quarter and plans to double production of its high-stakes gene therapies.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

HVAC giant AAON reports record 2025 sales but lower earnings due to massive investments. A $1.83B backlog signals a powerful 2026 rebound.

Nike's rescheduled Q3 earnings report on March 31 amplifies anxiety as the giant battles tariffs, a China slump, and deep market skepticism.